Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Portfolio Pulse from Lara Goldstein
Cybin (NYSE:CYBN) has announced its acquisition of UK-based Small Pharma (OTCQB:DMTTF). The deal has been approved by both companies' boards and will next face Cybin’s shareholders meeting on October 12. Small Pharma shareholders will receive 0.2409 Cybin common shares per each common share held. Post-acquisition, Cybin shareholders and Small Pharma security holders would own approximately 74.5% and 25.5% of Cybin, respectively. The combined company will continue to trade on NYSE and Cboe Canada under the ticker “CYBN”. The acquisition is expected to create a market leader in psychedelic therapeutics.
August 28, 2023 | 5:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cybin's acquisition of Small Pharma could strengthen its position in the market of psychedelic therapeutics.
The acquisition of Small Pharma by Cybin could potentially strengthen Cybin's market position by expanding its portfolio and creating a larger dataset of systematic research. This could potentially lead to an increase in Cybin's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Small Pharma's acquisition by Cybin could lead to its delisting from TSXV and OTCQB.
As a result of the acquisition, Small Pharma's shares would be delisted from both TSXV and OTCQB. This could potentially lead to a decrease in Small Pharma's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100